Overview of Amyotrophic Lateral Sclerosis (ALS)
ALS is a devastating neurodegenerative disorder primarily affecting motor neurons in the brain and spinal cord. This progressive condition disrupts communication between neurons and muscles, leading to muscle weakness, atrophy, and eventual paralysis. ALS typically manifests between ages 40 and 70, with symptoms such as muscle twitches, cramps, and difficulty with voluntary movements.
As the disease advances, individuals may experience challenges with speaking, swallowing, and breathing. Interestingly, ALS does not usually impact cognitive function or sensory abilities. The condition exists in two forms: sporadic ALS, accounting for 90% of cases, and familial ALS, which is inherited and comprises about 10% of cases[1].
How ALS Affects Facial Muscles
Early Facial Symptoms of ALS
Weakness in facial muscles
Weakness in facial muscles is a hallmark symptom of ALS, particularly in cases of bulbar onset. As the disease progresses, individuals may experience atrophy and weakness in the muscles of the face, tongue, and jaw. This can lead to difficulties in speech articulation, with people developing slurred or thick speech (dysarthria)[2].
The tongue may become atrophic and weak, with visible fasciculations, ultimately lying useless on the floor of the mouth. Facial weakness can also result in problems with chewing and swallowing (dysphagia), as well as ineffective closure of the nasopharynx, potentially causing fluid regurgitation through the nose[2].
Changes in facial expressions
Changes in facial expressions are a significant aspect of ALS progression, impacting an individual’s ability to convey emotions and communicate non-verbally. As the disease affects motor neurons controlling facial muscles, people may experience a gradual loss of facial expressiveness. This can manifest as a reduced range of motion in facial features, such as difficulty smiling, frowning, or raising eyebrows.
The diminished ability to form expressions can lead to a mask-like appearance, often referred to as a “flat affect.” This alteration in facial mobility not only affects emotional communication but can also contribute to social isolation and misunderstandings, as others may misinterpret the lack of expression as disinterest or apathy[3].
Advanced Facial Symptoms in ALS
Drooling and excess saliva production
Drooling and excess saliva production, known as sialorrhea, is a common and distressing symptom in people with ALS. Contrary to popular belief, this condition is not caused by increased saliva production but rather by a decreased ability to swallow secretions due to bulbar muscle weakness, tongue spasticity, and impaired orofacial muscle control.
Approximately 50% of people with ALS report significant sialorrhea at some point during their disease progression, with about 20% experiencing moderate to severe symptoms. The accumulation of saliva can lead to various complications, including impaired speech production, compromised lung function, difficulties with non-invasive ventilation, and an increased risk of aspiration pneumonia[4].
Speech and swallowing difficulties
Speech and swallowing difficulties are hallmark symptoms of ALS, significantly impacting quality of life. Bulbar impairment, a pathognomonic feature of ALS, leads to the development of oropharyngeal dysphagia in approximately 30% of people at disease onset, with almost all experiencing these symptoms as the disease progresses.
The underlying mechanisms of tongue motor dysfunction, a major risk factor for aspiration, are not fully understood. Dysphagia in ALS is also related to impairments in the upper aerodigestive tract, respiratory, and laryngeal muscles, affecting the expiratory phase of voluntary cough[5].
Diagnosing Facial ALS Symptoms
Electromyography (EMG) and nerve conduction studies
Electromyography (EMG) and nerve conduction studies are crucial diagnostic tools in evaluating people with suspected ALS. EMG involves inserting a needle electrode into various muscles to record their electrical activity both at rest and during contraction. This test can detect signs of denervation, such as fibrillation potentials and positive sharp waves, as well as changes in motor unit potentials indicative of reinnervation.
Nerve conduction studies assess the ability of nerves to transmit electrical signals and can help rule out other conditions that may mimic ALS. These studies typically reveal normal sensory responses but may show reduced compound muscle action potential (CMAP) amplitudes in affected muscles[6].
Differential diagnosis and ruling out other conditions
Differential diagnosis is crucial when evaluating people with suspected ALS, as several conditions can mimic its presentation. Careful clinical evaluation, electrophysiological studies, and in some cases, genetic testing or muscle biopsy, are essential to differentiate these conditions from ALS and ensure appropriate management[7].
Managing Facial Symptoms in ALS
Medications to control excess saliva
Several medications can be employed to control excess saliva production in people with ALS. Anticholinergic drugs are often the first-line treatment, with scopolamine patches showing effectiveness in 85% of treated subjects, although half may require additional therapies[8].
For those who do not respond to anticholinergics, botulinum toxin injections into the salivary glands have shown promise. Both serotypes A and B have demonstrated efficacy, with effects lasting up to 3-6 months[8].
Speech therapy and communication aids
Speech therapy plays a crucial role in managing facial symptoms of ALS, particularly in maintaining effective communication as the disease progresses. Speech-language pathologists (SLPs) employ various strategies to address the challenges posed by dysarthria, a common symptom characterized by slow, slurred, breathy, or hoarse speech.
As verbal communication becomes more challenging, Augmentative and Alternative Communication (AAC) tools become essential. These include Text-To-Speech Apps, Speech Generating Devices, and Low-Tech Communication Methods. SLPs also emphasize the importance of message and voice banking early in the disease progression to preserve the person’s unique cadence and delivery[9].
At ALS United Greater Chicago, we offer comprehensive Care Services to support individuals with ALS and their families throughout their journey. Our team of experts provides personalized care plans, including speech therapy and access to communication aids, to help maintain quality of life and independence.
Research and Future Directions
Current studies on facial symptom management
Current studies on facial symptom management in ALS are exploring innovative approaches to address the challenges faced by people with the condition. One promising area of research involves the use of precision medicine and biomarkers to tailor treatments to individual people.
Additionally, researchers are investigating the use of neurofilament light chain (NfL) in cerebrospinal fluid and blood as a biomarker for disease progression and treatment response. This non-invasive measure could enable earlier decisions regarding treatment efficacy in clinical trials, potentially allowing people to switch to new trial agents more quickly[10].
Emerging therapies for ALS facial symptoms
Emerging therapies for ALS facial symptoms are focusing on innovative approaches to address the complex pathophysiology of the disease. One promising avenue is the development of antisense oligonucleotides (ASOs) targeting specific genetic mutations. Stem cell therapies, including neural stem cells (NSCs) and mesenchymal stem cells (MSCs), are also being explored for their potential to protect damaged neurons and replace lost cells[11].
Conclusion
Understanding and managing facial symptoms in ALS is crucial for maintaining quality of life and effective communication. At ALS United Greater Chicago, we are committed to providing comprehensive support and care for individuals affected by ALS and their families. Our dedicated team offers a range of services, from speech therapy to access to cutting-edge assistive technologies.
As research continues to advance, we remain hopeful for new treatments and therapies that can improve symptom management and potentially slow disease progression. We encourage you to reach out and learn more about how we can support you or your loved ones on this journey. Together, we can make a difference in the lives of those affected by ALS.
Donate Now to support our mission and help us continue providing essential services to the ALS community.
- Johns Hopkins Medicine. (n.d.). Amyotrophic Lateral Sclerosis (ALS).
- Orsini, M., Oliveira, A. B., Nascimento, O. J. M., et al. (2022). Amyotrophic Lateral Sclerosis: Clinical Features and Diagnosis. In StatPearls. StatPearls Publishing.
- National Institute of Neurological Disorders and Stroke. (2022). Amyotrophic Lateral Sclerosis (ALS) Fact Sheet.
- Banfi, P., Ticozzi, N., Lax, A., et al. (2015). A Review of Options for Treating Sialorrhea in Amyotrophic Lateral Sclerosis. Respiratory Care, 60(3), 446-454.
- Orsini, M., Oliveira, A. B., Reis, C. H. M., et al. (2022). Oropharyngeal Dysphagia in Amyotrophic Lateral Sclerosis: From Pathophysiology to Therapeutic Strategies. Neurology International, 14(2), 259-270.
- Geevasinga, N., Menon, P., Scherman, D. B., et al. (2016). Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. Neurology, 87(7), 684-690.
- Hardiman, O., Al-Chalabi, A., Brayne, C., et al. (2017). The changing picture of amyotrophic lateral sclerosis: lessons from European registers. Journal of Neurology, Neurosurgery & Psychiatry, 88(7), 557-563.
- Banfi, P., Ticozzi, N., Lax, A., et al. (2015). A Review of Options for Treating Sialorrhea in Amyotrophic Lateral Sclerosis. Respiratory Care, 60(3), 446-454.
- Speak Live Play. (n.d.). ALS Speech Therapy.
- Benatar, M., Turner, M. R., & Wuu, J. (2020). Defining pre-symptomatic amyotrophic lateral sclerosis. Nature Reviews Neurology, 16(5), 271-282.
- Mejzini, R., Flynn, L. L., Pitout, I. L., et al. (2019). ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Frontiers in Neuroscience, 13, 1310.
